Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
21 results
D2.19 - Can Drug Provocation Be Avoided in Low-Risk Quinolone Reactions?
D2.17 - Diagnostic profitability of penicilloyl-polylysine and minor determinant mixture in urgent/preferred beta-lactam allergy studies in hospitalized patients from january 2023 to december 2025
D2.20 - Selective Fixed Drug Eruption from Etoricoxib with Safe Celecoxib Use: Role of Patch Testing
D2.21 - The Cyto-LTT: A multiplex cytokine assay to detect and assess the strength of T cell reactivity in drug hypersensitivity
D2.29 - Use and knowledge of Phadiatop Infant and Fx5 in children from a primary care healthcare area
D3.213 - Sustained effectiveness of the 300 IR house dust mite sublingual tablet over 2 treatment years in a real-world data setting – results of a non-interventional study
D3.198 - Challenges of using clinical scores as primary endpoints in allergology trials
D3.199 - Severe systemic allergic reaction following violation of elimination diet in a patient with sensitization despite achieved remission on allergen-specific immunotherapy
D3.200 - Broad profile of olive pollen sensitisation as a key factor in immunotherapy failure
D3.201 - Subcutaneous immunotherapy with a depigmented cat allergoid is safe in patients with cat allergy and beneficial for mental health in adolescents
D3.205 - Two-year Outcomes of Multiple Low-Dose Oral Immunotherapies for combination of Tree Nuts or Peanut for Severe Allergy Patients
D3.207 - Symptomatology and Sensitization Profiles of Patients Undergoing Subcutaneous Immunotherapy for Aeroallergens in Greece
D3.209 - Subcutaneous Allergen Immunotherapy in Children: Frequency of Local and Systemic Adverse Reactions and Associated Risk Factors
D3.232 - The AhR agonist tapinarof suppresses human skin inflammation by inducing metabolic reprogramming and reducing production of mitochondrial pro-inflammatory DAMPs
D3.231 - Gut Microbiome Dysbiosis in Antihistamine-Refractory Chronic Spontaneous Urticaria and Its Association with Disease Characteristics- A Cross-Sectional Case–Control Analysis
D3.233 - Polypharmacy-Associated Lichenoid Eruption Simulating Keratosis Lichenoides Chronica
D3.234 - Successful Use of Ritlecitinib in Long-Standing Alopecia Areata with Previous JAK Inhibitor Failure
D3.236 - Does Night Work Influence the Severity of Allergic Contact Dermatitis ?
D3.237 - Specific Features of Allergic Contact Dermatitis in Diabetic Patients in a Dermato-Allergology Unit in Tunisia
D3.238 - Allergic Contact Dermatitis to Formaldehyde: A 31-Year Experience in a Dermato-Allergology Consultation
Pagination
Current page
1
Page
2
Next page
Next
Last page
Last
Download the app
The congress at your fingertips
Available on
Download